

Drug utilisation patterns in Zabljak municipality, Serbia and Montenegro

Sipcic M, MD Jankovic SV, MD Jankovic, SM, MD, PhD, MA Medical Faculty, University of Kragujevac, Kragujevac, Serbia and Montenegro

Correspondence to: Prof Slobodan M Jankovic, e-mail: slobnera@EUnet.yu

Abstract

Background

Information about drug utilisation among outpatients in Serbia and Montenegro is scanty, and no publications on the topic are available. The objective of this study was thus to evaluate and compare patterns of drug utilisation in the Zabljak municipality.

Methods

Prescriptions for outpatients (n=456) and dispensing records from a local pharmacy in Zabljak for a threemonth period were reviewed retrospectively.

Results

The leading diagnoses were infectious diseases of the respiratory system and hypertension. The total number of defined daily doses (DDD) per 1 000 inhabitants per day was 178.75. Cardiovascular drugs (41.139 DDD/1 000/day), drugs for the gastrointestinal system (36.881 DDD/1 000/day) and antibacterial drugs (18.318 DDD/ 1 000/day) were the most frequently prescribed drugs.

Conclusion

The total number of drugs utilised per 1 000 inhabitants per day was within the acceptable range. However, the pattern of diagnosis did not correspond to the pattern of drug utilisation. There is a need for intervention in order to promote the rational selection and use of drugs among outpatients in Serbia and Montenegro.

SA Fam Pract 2007;49(1):16

The full version of this article is available at: www.safpj.co.za

P This article has been peer reviewed

Introduction

Drug utilisation statistics are an important tool with which to evaluate the quality of prescribing in a defined setting.1 Although significant efforts have been made to introduce the principles of rational drug use worldwide, the situation is still far from ideal.^{2,3} There are many reasons for this situation, including: (1) a lack of national guidelines for the treatment of mass diseases in some countries; (2) no system for the provision of continuing medical education in some countries; (3) the retention of obsolete drugs in the market; (4) medical practice not based on evidence; and (5) pressure from pharmaceutical companies.4,5 Serbia and Montenegro is a country in socio-economical transition, with a high burden of poverty and many refugees. The country faces some of the abovementioned problems.6 The aim of this study was to investigate patterns of drug use in the semi-rural municipality of Zabljak, which could be considered a typical municipality in Serbia and Montenegro.

Methods

This is a cross-sectional study of drug utilisation in the Zabliak municipality. which is located in the mountainous area of Serbia and Montenegro and has 4 880 inhabitants. The study was conducted from January to March in 2001. There was only one primary care health facility in Zabljak where prescribing was done, and only one state pharmacy, where prescribed drugs were dispensed. During the abovementioned period, the following data were collected from prescriptions and dispensing records: initials, sex and age of the patients, diagnosis, drugs dispensed, and the doses of the

Drug utilisation was calculated using the methodology of the World Health Organization,⁷ and expressed in defined daily doses (DDDs) per 1 000 inhabitants per day. The diagnoses were classified according to the tenth revision of the International Classification of Diseases.⁸

Results

The total number of patients for the study period was 465. Of these, 259 (56%) were adults (124 males and 135 females) and 206 (44%) were children younger than 14 years (109 boys and 97 girls). Since Zabljak municipality is remote and isolated, the physicians only prescribed drugs that were available in the local pharmacy. The total

drug utilisation was 178.75 DDD/1 000 inhabitants/day. The drugs comprising 90% of the total drug utilisation are shown in Table I, classified according to the Anatomic-Therapeutic-Chemical ATC classification. The diagnoses comprising 90% of all diagnoses for both adults and children are given in Table II. The number of diagnoses (411) was less than the number of patients (465); the remaining 54 patients did not have diagnoses in their dispensing records.

Discussion

Overall drug utilisation in Zabljak was not higher than in other countries, including developed ones.⁹ However, the patterns of drug utilisation point to certain irrationalities.

The first problem we observed was related to the utilisation of anti-hypertensive drugs. The total quantity of all anti-hypertensive drugs used was about 30 DDD/1 000 inhabitants/day; at the same time, only 31 patients were diagnosed as having hypertension, which implies everyday drug therapy. Since Zabljak has 4 880 inhabitants, this means that there were about six hypertensive patients per 1 000 inhabitants. At first glance it appeared that each hypertensive patient was taking on average about five drugs with an anti-hypertensive action (diuretics. ACE inhibitors, beta-blockers or calcium-channel antagonists). However, since diuretics and ACE inhibitors could also be used for heart failure and beta-blockers or calcium-channel inhibitors for diseases of the coronary artery, these drugs could have been patients/1 000 used for another four inhabitants/day suffering from these two diseases. This leads to an average of three anti-hypertensive drugs for the patients with hypertension, which is still too high. Only exceptional hypertension should be treated with more than two drugs (in about 20% of patients). and there is no reason to believe that all of the patients required such a regimen.10

Over-utilisation was also observed with drugs against angina pectoris. Tables I and II indicate that there were three patients with angina pectoris per 1 000 inhabitants, while around 15 DDDs of anti-anginal drugs were dispensed per 1 000 inhabitants every day. Even if half of this drug utilisation is ascribed to anti-hypertensive treatment (beta blockers and calcium-channel antagonists also could be used for this indication), it remains that three to five antianginal drugs were used per patient.

Since angina pectoris is treated mostly with a combination of two anti-anginal drugs, it seems that polypharmacy occurred.¹¹

Regarding antibiotic utilisation, it is clear from Table I that the total consumption was around 18 DDDs/1 000 inhabitants/day. About 280 patients (both adults and children) were suffering from infections, and if one considers the five-day duration of a course of treatment for an infection, it means that there were 90/5 = 18 disease courses during the study period. Furthermore, it means that 280/18 = 15.6 patients had an infection every day. Since 18 DDDs were utilised for these 15.6 patients, it appears that each patient with an infection was receiving at least one antibiotic. According to other studies, at most 50% of patients with an infection should receive antibiotics. 12 which points to over-prescribing of antibiotics in this case.

Vitamins were also over-utilised, at 20 DDDs/1 000 inhabitants/day. However, over-utilisation of vitamins is not an isolated phenomenon specific to Zabljak. In a survey done in Germany, 4 030 persons aged from 18 to 79 were asked about their dietary habits, including vitamin and mineral supplement use. About 43% of the population reported using supplements at least once in the observation period of 12 months. ¹³ In Spain, 34.6% of all drugs sold in community pharmacies are vitamins. ¹⁴

The utilisation of drugs that decrease hydrochloric acid secretion in the stomach (ranitidine, famotidine and omeprazole) was also inappropriately high. Only 10 patients had an indication for the use of these drugs (five patients with ulcer and five patients with gastritis, which is equal to two patients/1 000 inhabitants/day), while 10 DDDs/1 000 inhabitants/day of these drugs were utilised. This means that eight out of 10 patients who were taking H_a blockers or a proton pump inhibitor had no rational reason to do so. This figure is much higher than the situation in primary care in the USA, where around 61% of patients with definite indications were found to be taking H, blockers or proton pump inhibitors. 15

Finally, anti-asthmatic medication was dispensed in higher quantities than actually needed. There were 1.6 patients with bronchial asthma or chronic obstructive pulmonary disease per 1 000 inhabitants – the only ones who may have reason to use anti-asthmatic drugs. Even if each patient was

Table I: Drugs whose utilisation comprised 90% of the total drug utilisation (in DDD/1 000 inhabitants/ day) in Zabljak municipality during a three-month period

		777	
Group A	Drugs for gastrointestinal tract and metabolism	DDD/1 000 inhabitants/day	
A02	Antacids, ulcer-healing drugs and carminative agents		
	Ranitidine	5.328	
	Famotidine	2.459	
	Omeprazole	2.104	
A02 total		9.891	
A06	Drugs for Constipation		
	Bisacodyl	0.847	
A06 total		0.847	
A07	Antidiarrhoeal, anti-infectious and intestinal anti-inflammatory drugs		
	Nystatin	0.649	
	Loperamide	0.601	
	Bacillus IP 5832	1.202	
A07 total		2.452	
A10	Oral antidiabetic drugs		
	Glibenclamide	1.298	
	Chlorpropamide	1.093	
A10 total		2.562	
A11	Vitamins		
	Vitamin A+D	6.375	
	Vitamin B group	1.229	
	Ascorbic acid	11.202	
	Combinations of vitamins and minerals	1.366	
A11 total		20.172	
A12	Minerals		
ALE .	Calcium	0.956	
A12 total	Carolan	0.956	
A group: 36.881 DDD/1 000 inhabitar	nte/day	0.530	
Group B	Blood and blood-forming organs	DDD/1 000 inhabitants/day	
B01	Anticoagulants	DDD/1 000 Illiabitants/day	
501		0.512	
B01 total	Ticlopidine	0.512	
	During wood in greening	0.512	
B03	Drugs used in anaemias		
	Ferrous sulphate	0.717	
B03 total		A = 4 =	
B group: 1.229 DDD/1 000 inhabitant		0.717	
C group	Cardiovascular drugs	0.717 DDD/1 000 inhabitants/day	
C group	Cardiovascular drugs Treatment of cardiac diseases	DDD/1 000 inhabitants/day	
	Cardiovascular drugs		
	Cardiovascular drugs Treatment of cardiac diseases Digoxin Amiodarone	DDD/1 000 inhabitants/day 2.596 0.546	
	Cardiovascular drugs Treatment of cardiac diseases Digoxin Amiodarone Pentaerythritol tetranitrate	2.596 0.546 5.707	
	Cardiovascular drugs Treatment of cardiac diseases Digoxin Amiodarone	DDD/1 000 inhabitants/day 2.596 0.546	
	Cardiovascular drugs Treatment of cardiac diseases Digoxin Amiodarone Pentaerythritol tetranitrate	2.596 0.546 5.707	
C01	Cardiovascular drugs Treatment of cardiac diseases Digoxin Amiodarone Pentaerythritol tetranitrate Isosorbide dinitrate	2.596 0.546 5.707	
	Cardiovascular drugs Treatment of cardiac diseases Digoxin Amiodarone Pentaerythritol tetranitrate Isosorbide dinitrate Glyceryl trinitrate	2.596 0.546 5.707 0.607	
C01	Cardiovascular drugs Treatment of cardiac diseases Digoxin Amiodarone Pentaerythritol tetranitrate Isosorbide dinitrate Glyceryl trinitrate	2.596 0.546 5.707 0.607 0.892	
C01 total	Cardiovascular drugs Treatment of cardiac diseases Digoxin Amiodarone Pentaerythritol tetranitrate Isosorbide dinitrate Glyceryl trinitrate Isosorbide-mononitrate	2.596 0.546 5.707 0.607 0.892	
C01 total	Cardiovascular drugs Treatment of cardiac diseases Digoxin Amiodarone Pentaerythritol tetranitrate Isosorbide dinitrate Glyceryl trinitrate Isosorbide-mononitrate Diuretics	DDD/1 000 inhabitants/day 2.596 0.546 5.707 0.607 0.892 1.503 11.851	
C01 total	Cardiovascular drugs Treatment of cardiac diseases Digoxin Amiodarone Pentaerythritol tetranitrate Isosorbide dinitrate Glyceryl trinitrate Isosorbide-mononitrate Diuretics Indapamide	DDD/1 000 inhabitants/day 2.596 0.546 5.707 0.607 0.892 1.503 11.851	
C01 total	Cardiovascular drugs Treatment of cardiac diseases Digoxin Amiodarone Pentaerythritol tetranitrate Isosorbide dinitrate Glyceryl trinitrate Isosorbide-mononitrate Diuretics Indapamide Furosemide	DDD/1 000 inhabitants/day 2.596 0.546 5.707 0.607 0.892 1.503 11.851 5.191 0.911	
C01 total	Cardiovascular drugs Treatment of cardiac diseases Digoxin Amiodarone Pentaerythritol tetranitrate Isosorbide dinitrate Glyceryl trinitrate Isosorbide-mononitrate Diuretics Indapamide Furosemide Bumetanide	DDD/1 000 inhabitants/day 2.596 0.546 5.707 0.607 0.892 1.503 11.851 5.191 0.911 1.184	
C01 total C03	Cardiovascular drugs Treatment of cardiac diseases Digoxin Amiodarone Pentaerythritol tetranitrate Isosorbide dinitrate Glyceryl trinitrate Isosorbide-mononitrate Diuretics Indapamide Furosemide Bumetanide	DDD/1 000 inhabitants/day 2.596 0.546 5.707 0.607 0.892 1.503 11.851 5.191 0.911 1.184 1.002	

C group	Cardiovascular drugs	DDD/1 000 inhabitants/day	
C04 total		1.22	
C07	Beta-adrenoceptor blocking drugs		
	Propranolol Propranolol	0.541	
	Metoprolol	2.96	
	Atenolol	2.805	
C07 total		6.306	
C08	Calcium-channel blockers		
	Nifedipine	4.091	
	Verapamil	1.594	
	Diltiazem	1.46	
C08 total		7.145	
C09	ACE inhibitors		
	Captopril	4.053	
	Enalapril	0.728	
	Quinapril	1.548	
C09 total		6.329	
C group: 41.139 DDD/1 000 inhabitar	nts/day		
H group	Hormones	DDD/1 000 inhabitants/day	
H02	Glucocorticoids	,	
	Dexamethasone	0.045	
	Prednisolone	0.569	
H02 total	Todaliscione	0.614	
H03	Thyroid hormones		
	Carbimazole	1.275	
H03 total		1.275	
H group: 1.889 DDD/1 000 inhabitant	ls/dav		
J group	Antibacterial drugs	DDD/1 000 inhabitants/day	
J01	Antibiotics	,	
	Ampicillin	2.025	
	Amoxicillin	8.866	
	Penicillin G benzathine	0.914	
	Cefalexin	2.339	
	Cefaclor	0.581	
	Cefaclor Co-trimoxazole		
		0.581 2.425 1.161	
J01 total	Co-trimoxazole	2.425	
J01 total J group: 18.318 DDD/1 000 inhabitan	Co-trimoxazole Azithromycin	2.425	
	Co-trimoxazole Azithromycin	2.425	
J group: 18.318 DDD/1 000 inhabitan	Co-trimoxazole Azithromycin	2.425 1.161 18.311	
J group: 18.318 DDD/1 000 inhabitan M group	Co-trimoxazole Azithromycin hts/day Drugs for musculoskeletal disorders	2.425 1.161 18.311	
J group: 18.318 DDD/1 000 inhabitan M group	Co-trimoxazole Azithromycin hts/day Drugs for musculoskeletal disorders Non-steroidal anti-inflammatory drugs	2.425 1.161 18.311 DDD/1 000 inhabitants/day	
J group: 18.318 DDD/1 000 inhabitan	Co-trimoxazole Azithromycin hts/day Drugs for musculoskeletal disorders Non-steroidal anti-inflammatory drugs Indometacin	2.425 1.161 18.311 DDD/1 000 inhabitants/day 4.098	
J group: 18.318 DDD/1 000 inhabitan	Co-trimoxazole Azithromycin hts/day Drugs for musculoskeletal disorders Non-steroidal anti-inflammatory drugs Indometacin Diclofenac	2.425 1.161 18.311 DDD/1 000 inhabitants/day 4.098 10.715	
J group: 18.318 DDD/1 000 inhabitan	Co-trimoxazole Azithromycin nts/day Drugs for musculoskeletal disorders Non-steroidal anti-inflammatory drugs Indometacin Diclofenac Piroxicam	2.425 1.161 18.311 DDD/1 000 inhabitants/day 4.098 10.715 1.184	
J group: 18.318 DDD/1 000 inhabitan M group	Co-trimoxazole Azithromycin Ints/day Drugs for musculoskeletal disorders Non-steroidal anti-inflammatory drugs Indometacin Diclofenac Piroxicam Acetylsalycilic acid	2.425 1.161 18.311 DDD/1 000 inhabitants/day 4.098 10.715 1.184 4.554	
J group: 18.318 DDD/1 000 inhabitan M group	Co-trimoxazole Azithromycin hts/day Drugs for musculoskeletal disorders Non-steroidal anti-inflammatory drugs Indometacin Diclofenac Piroxicam Acetylsalycilic acid Noraminophenazone	2.425 1.161 18.311 DDD/1 000 inhabitants/day 4.098 10.715 1.184 4.554 2.087	
J group: 18.318 DDD/1 000 inhabitan M group	Co-trimoxazole Azithromycin hts/day Drugs for musculoskeletal disorders Non-steroidal anti-inflammatory drugs Indometacin Diclofenac Piroxicam Acetylsalycilic acid Noraminophenazone Paracetamol	2.425 1.161 18.311 DDD/1 000 inhabitants/day 4.098 10.715 1.184 4.554 2.087 0.587	
J group: 18.318 DDD/1 000 inhabitan M group M01	Co-trimoxazole Azithromycin Ints/day Drugs for musculoskeletal disorders Non-steroidal anti-inflammatory drugs Indometacin Diclofenac Piroxicam Acetylsalycilic acid Noraminophenazone Paracetamol Ibuprofen	2.425 1.161 18.311 DDD/1 000 inhabitants/day 4.098 10.715 1.184 4.554 2.087 0.587 3.104	
J group: 18.318 DDD/1 000 inhabitan M group M01 M01 total	Co-trimoxazole Azithromycin Ints/day Drugs for musculoskeletal disorders Non-steroidal anti-inflammatory drugs Indometacin Diclofenac Piroxicam Acetylsalycilic acid Noraminophenazone Paracetamol Ibuprofen	2.425 1.161 18.311 DDD/1 000 inhabitants/day 4.098 10.715 1.184 4.554 2.087 0.587 3.104	
J group: 18.318 DDD/1 000 inhabitan M group M01 M01 M01 total M group: 25.742 DDD/1 000 inhabitan	Co-trimoxazole Azithromycin Ints/day Drugs for musculoskeletal disorders Non-steroidal anti-inflammatory drugs Indometacin Diclofenac Piroxicam Acetylsalycilic acid Noraminophenazone Paracetamol Ibuprofen	2.425 1.161 18.311 DDD/1 000 inhabitants/day 4.098 10.715 1.184 4.554 2.087 0.587 3.104 25.742	
J group: 18.318 DDD/1 000 inhabitan M group M01 M01 M01 total M group: 25.742 DDD/1 000 inhabitan	Co-trimoxazole Azithromycin hts/day Drugs for musculoskeletal disorders Non-steroidal anti-inflammatory drugs Indometacin Diclofenac Piroxicam Acetylsalycilic acid Noraminophenazone Paracetamol Ibuprofen hts/day Drugs acting on nervous system	2.425 1.161 18.311 DDD/1 000 inhabitants/day 4.098 10.715 1.184 4.554 2.087 0.587 3.104 25.742	
J group: 18.318 DDD/1 000 inhabitan M group M01 M01 M01 total M group: 25.742 DDD/1 000 inhabitan	Co-trimoxazole Azithromycin Ints/day Drugs for musculoskeletal disorders Non-steroidal anti-inflammatory drugs Indometacin Diclofenac Piroxicam Acetylsalycilic acid Noraminophenazone Paracetamol Ilbuprofen Ints/day Drugs acting on nervous system Antimigraine drugs	2.425 1.161 18.311 DDD/1 000 inhabitants/day 4.098 10.715 1.184 4.554 2.087 0.587 3.104 25.742 DDD/1 000 inhabitants/day	
J group: 18.318 DDD/1 000 inhabitan M group M01 M01 total M group: 25.742 DDD/1 000 inhabitan N group	Co-trimoxazole Azithromycin Ints/day Drugs for musculoskeletal disorders Non-steroidal anti-inflammatory drugs Indometacin Diclofenac Piroxicam Acetylsalycilic acid Noraminophenazone Paracetamol Ilbuprofen Ints/day Drugs acting on nervous system Antimigraine drugs	2.425 1.161 18.311 DDD/1 000 inhabitants/day 4.098 10.715 1.184 4.554 2.087 0.587 3.104 25.742 DDD/1 000 inhabitants/day	

SA Fam Pract 2007:49(1) 16 c

N group	Drugs acting on nervous system	DDD/1 000 inhabitants/day	
N03 total		5.191	
N05	Psycholeptics		
	Haloperidol	0.81	
	Diazepam	4.023	
	Bromazepam	1.055	
	Prazepam	0.637	
N05 total		5.078	
N group: 11.669 DDD/1 000 inhabitar	nts/day		
R group	Drugs for respiratory system	DDD/1 000 inhabitants/day	
R01	Nasal formulations		
	Phenylephrine , trimazoline	4.554	
R01 total		4.554	
R03	Bronchodilators		
	Salbutamol	0.592	
	Fenoterol, ipatropium	11.612	
	Aminophylline	0.645	
R03 total		11.612	
R05	Dugs against cough and common cold		
	Bromhexine	4.401	
R05 total		4.401	
R06	Antihistamines		
	Astemizole	0.911	
R06 total		0.911	
R group: 21.478 DDD/1 000 inhabitar	nts/day		
S group	Drugs for eye and ears	DDD/1 000 inhabitants/day	
S01	Drugs for eye		
	Dexamethasone plus neomycin	0.763	
	Naphazoline	1.764	
S01 total		2.527	
S group: 2.527 DDD/ 1000 inhabitant	s/day		
TOTAL 90% UTILISATION: 160.872 D	DD/1 000 inhabitants/day		

Table II: Diagnoses in the patients comprising 90% of all conditions (n=465)

Code	Diagnosis	Number of patients and percentage	Females	Males
J02	Acute pharyngitis	156 (37.8%)	77	79
J00	Acute nasopharyngitis ("common cold")	41 (9.8%)	20	21
I10	Primary hypertension	31 (7.4%)	26	5
J20	Acute bronchitis	27 (6.5%)	15	12
R50	Fever of unknown origin	23 (6.4%)	12	11
R05	Cough	16 (3.8%)	8	8
120	Angina pectoris	15 (3.5%)	7	8
N39	Urinary tract infection	12 (2.9%)	7	5
J01	Acute sinusitis	11 (2.7%)	4	7
M54	Back pain	10 (2.4%)	4	6
J18	Pneumonia	10 (2.4%)	4	6
R51	Headache	8 (1.9%)	4	4
K26	Peptic ulcer disease	5 (1.2%)	2	3
K29	Gastritis	5 (1.2%)	3	2
R55	Syncope	5 (1.2%)	3	2
H10	Conjunctivitis	5 (1.2%)	4	1
G40	Epilepsy	4 (1%)	3	1
J44	Chronic obstructive pulmonary disease (COPD)	4 (1%)	1	3
J45	Asthma	4 (1%)	4	0

Code	Diagnosis	Number of patients and percentage	Females	Males
L50	Urticaria	4 (1%)	4	0
N23	Renal colic	4 (1%)	1	3
S61	Wounds	4 (1%)	4	0
142	Heart failure	4 (1%)	2	2
J05	Acute laryngitis	3 (0.7%)	2	1
TOTAL		411 (100%)	221	190

using three different anti-asthmatic drugs, this would amount to 5 DDDs/1 000 inhabitants/day. Yet 12 DDDs/1 000 inhabitants/day were being used (dispensed), probably because the patients were creating personal drug stocks. This practice should not be tolerated, because it bears two negative consequences: a drug overdose or poisoning becomes more possible, and the drug budget is not distributed evenly throughout the fiscal year. ¹⁶

Conclusion

It would appear that drugs are not being used rationally in this small, isolated community. This leads to the need for significant interventions in the education of general practitioners and for the adoption of a clear drug policy in primary care in the Zabljak municipality of Serbia and Montenegro.¹⁶

References

- Dukes MNG, editor. Drug utilization studies: methods and uses. WHO Regional Publications. Eur Ser No 45. Copenhagen: WHO Regional Office for Europe; 1993.
- Gonzalez ER, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997;278:901-4.
- Ogunnowo BE, Asuzu MC. Evaluation of rational prescribing practices of doctors and medical students at the Igbo-Ora Comprehensive Hospital, Nigeria. Niger J Med 2003;12:39-42.
- Flores W, Ochoa H, Briggs J, Garcia R, Kroeger A. Economic costs associated with inadequate drug prescribing: an exploratory study in Chiapas, Mexico. Acta Trop 2003;88:57-68.
- Rishi RK, Sangeeta S, Surendra K, Tailang M. Prescription audit: experience in Garhwal (Uttaranchal), India. Trop Doct 2003;33:76-9.
- Budak A, Babic-Banaszak A, Katic M, Vuletic S. Analysis of the health care system transition: what the health care users think. Lijec Vjesn 2003;125:32-5.
- Soos G. Importance of drug utilization studies as a pharmaceutical tool for the practice of evidence-based medicine. Acta Pharm Hung 2002;72:252-6.
- 3. Alexander S, Conner T, Slaughter T.

- Overview of inpatient coding. Am J Health Syst Pharm 2003;60(21 Suppl 6):S11-4.
- Gorecka K, Vlcek J, Walker R. Comparison of utilization of cardiovascular drugs in the Czech Republic and in Wales. Vnitr Lek 2003;49:592-7.
- Grzybowski A, Bellwon J, Gruchala M, et al. Effectiveness of hypertension treatment assessed by blood pressure level achieved in primary care setting in Poland. Blood Press 2003;12:232-8.
- 11. Noronha B, Duncan E, Byrne JA. Optimal medical management of angina. Curr Cardiol Rep 2003;5:259-65.
- Stone S, Gonzalez R, Maselli J, Lowenstein SR Antibiotic prescribing for patients with colds, upper respiratory tract infections, and bronchitis: A national study of hospital-based emergency departments. Ann Emerg Med 2000;36: 320-7.
- Beitz R, Mensink GB, Rams S, Doring A. Use of vitamin and mineral supplements in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2004;47:1057-65.
- Almazan La-Cave MD, Saavedra Santana P, Lainez Sevillano P, et al. Estimation of vitamin supplements and minerals consumption dispensed through pharmacy offices in the province of Las Palmas. An Med Interna 2005;22:469-72.
- Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol 2003:98:51-8
- Senior ML, Williams H, Higgs G. Morbidity, deprivation and drug prescribing: factors affecting variations in prescribing between doctors' practices. Health Place 2003;9:281-9.

SA Fam Pract 2007:49(1) 16 e